Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 18/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3038005 | 0.97 | HRH3 (0.77) | HRH3 | |
| SCHEMBL7139221 | 0.84 | LTA4H (0.75) | HRH3 | |
| SCHEMBL1239274 | 0.84 | HRH3 (0.74) | HRH3 | |
| SCHEMBL21348251 | 0.84 | HRH3 (0.66) | HRH3 | |
| SCHEMBL31010126 | 0.83 | HRH3 (0.84) | HRH3 | |
| SCHEMBL1241906 | 0.82 | HRH3 (0.78) | HRH3 | |
| Hydrochloric Acid SCHEMBL28582354 | 0.82 | HRH3 (0.71) | HRH3 | |
| SCHEMBL3031580 | 0.82 | HRH3 (0.78) | HRH3 | |
| SCHEMBL31484892 | 0.82 | HRH3 (0.78) | HRH3 | |
| SCHEMBL3041814 | 0.81 | HRH3 (0.57) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1311499-B1 | BICYCLIC COMPOUNDS AS H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARM INC (US) | 2006-04-12 | — | — | EP | claimed |
| EP-1311499-A2 | BICYCLIC COMPOUNDS AS H3 RECEPTOR LIGANDS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-05-21 | — | — | EP | claimed |
| US-20020037896-A1 | Pyrrole, furan, thiofuran and phenyl derivatives; inhibition of histamine H3 receptor activity; for example, 1-((4-(4-Pyrrolidin-1-ylmethyl-phenyl)-thien-2-yl)methyl)-pyrrolidine | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-03-28 | — | — | US | claimed |
| WO-2002012224-A2 | BICYCLIC COMPOUNDS AS H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-14 | — | — | WO | claimed |
| EP-1311499-B1 | BICYCLIC COMPOUNDS AS H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARM INC (US) | 2006-04-12 | — | — | EP | disclosed |
| US-6638967-B2 | Pyrrole, furan, thiofuran and phenyl derivatives; inhibition of histamine H3 receptor activity; for example, 1-((4-(4-Pyrrolidin-1-ylmethyl-phenyl)-thien-2-yl)methyl)-pyrrolidine | ORTHO-MCNEIL PHAMRACEUTICAL, INC. | 2003-10-28 | — | — | US | disclosed |
| EP-1311499-A2 | BICYCLIC COMPOUNDS AS H3 RECEPTOR LIGANDS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-05-21 | — | — | EP | disclosed |
| US-20020037896-A1 | Pyrrole, furan, thiofuran and phenyl derivatives; inhibition of histamine H3 receptor activity; for example, 1-((4-(4-Pyrrolidin-1-ylmethyl-phenyl)-thien-2-yl)methyl)-pyrrolidine | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-03-28 | — | — | US | disclosed |
| WO-2002012224-A2 | BICYCLIC COMPOUNDS AS H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037896-A1 | Pyrrole, furan, thiofuran and phenyl derivatives; inhibition of histamine H3 receptor activity; for example, 1-((4-(4-Pyrrolidin-1-ylmethyl-phenyl)-thien-2-yl)methyl)-pyrrolidine | HRH4, HRH3, HRH2 | HRH3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.